bioRxivImmunology
A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
C. O. Barnes, T. Schoofs, P. N. P. Gnanapragasam, J. Golijanin, K. E. Huey-Tubman, H. Gruell, P. Schommers, N. Suh-Toma, Y. E. Lee, J. C. C. Lorenzi, A. Piechocka-Trocha, J. F. Scheid, A. P. West, B. D. Walker, M. S. Seaman, F. Klein, M. C. Nussenzweig, P. J. Bjorkman
Abstract
The induction of broadly neutralizing antibodies (bNAbs) is a potential strategy for a vaccine against HIV-1. However, most bNAbs exhibit features such as unusually high somatic hypermutation, including insertions and deletions, which make their induction challenging. VRC01-class bNAbs exhibit extraordinary breadth and potency, but also rank among the most highly somatically-mutated bNAbs. Here we describe a VRC01-class antibody isolated from a viremic controller, BG24, that has less than half the mutations of most other relatives of its class, while achieving comparable breadth and potency. A 3.8 [A] X-ray crystal structure of a BG24-BG505 Env trimer complex revealed conserved contacts at the gp120 interface characteristic of the VRC01-class Abs, despite lacking common CDR3 sequence motifs. The existence of moderately-mutated CD4-binding site (CD4bs) bNAbs such as BG24 provides a simpler blueprint for CD4bs antibody induction by a vaccine, raising the prospect that such an induction might be feasible with a germline-targeting approach. TeaserAn anti-HIV-1 antibody with comparable neutralization breadth and potency to similarly-classed antibodies, with half as many mutations.
- organism: human
- assay: protein structure
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- HIV-1 CD4-binding site germline antibody-Env structures inform vaccine design
K.-M. A. Dam, C. O. Barnes, … P. J. Bjorkman·bioRxiv·Mar 25, 2022
- Dual Role of Glycosylation in Resistance to CD4-binding Site Broadly Neutralizing Antibodies
Teresa Anne Murphy, Meagan Kelly, … Rebecca M. Lynch·Journal of VirologyPeer-reviewed·Apr 3, 2026
- CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer
A. Schorcht, T. L. G. M. van den Kerkhof, … R. W. Sanders·bioRxiv·Mar 23, 2022
- Sequential vaccination matures VRC01-class HIV-1 neutralizing antibodies in humans
Tom G. Caniels, Madhu S. Prabhakaran, … Rogier W. Sanders·bioRxiv·Oct 26, 2026
- Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques
K. Saunders, J. Counts, … B. F. Haynes·bioRxiv·Mar 5, 2023
- CD4-binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals
H. B. Gristick, H. Hartweger, … P. J. Bjorkman·bioRxiv·Sep 8, 2022